Filing Flows › BridgeBio Pharma (BBIO) › Q2 2025
BridgeBio Pharma (BBIO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
BridgeBio Pharma (BBIO) reported revenue of $111M for the second quarter 2025 (Q2 2025), up 51-fold from a year earlier and -5% from the quarter before. Operating margin was -121.4%, net loss $184M (166.2% of revenue).
BridgeBio Pharma, Q2 2025: revenue $111M (51× year over year), operating margin -121.4%, net loss $184M, operating cash flow −$80.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $111M | -5% | 51× |
| Operating profit | −$134M | — | — |
| Net earnings | −$184M | — | — |
| Operating cash flow | −$80.7M | — | — |
What changed
Revenue was $110.6M in Q2 2025, up 5000% year over year and down 5% from the previous quarter. Net Product Revenue was the largest line at 65% of revenue. License and Services Revenue added $35.3M year over year (up 1627%), 33% of the total change.
Operating costs exceeded revenue by $134.3M, an operating margin of -121.4%. Total costs grew 38% against revenue growth of 5000%. The fastest-growing cost line was Cost of revenue (+511%). The quarter ended with a net loss of $183.8M, wider than the previous quarter's $169.6M loss. Minority interests bore $1.9M of it: to shareholders the quarter was a loss of $181.9M.
Operating cash flow was −$80.7M. Non-cash charges added back $1.3M of depreciation and amortization and $37.2M of share-based compensation. Working capital and other items added $64.5M. Capital expenditures of $594K exceeded it, leaving free cash flow of −$81.3M.
Questions
What was BridgeBio Pharma's revenue in the second quarter 2025?
BridgeBio Pharma (BBIO) reported revenue of $111M for the second quarter 2025 (Q2 2025), up 51-fold from a year earlier and -5% from the quarter before.
Was BridgeBio Pharma profitable in the second quarter 2025?
Operating loss was $134M (-121.4% of revenue) and net loss $184M.
Source: BridgeBio Pharma 10-Q on SEC EDGAR.